Drug · Small Molecule

Alvocidib

CI-DRUG-00000052Explore in graph →NCIt C74940 CHEMBL428690 CIViC Phase 3

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Trials	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	63	—	—	1997-07
Hodgkin Lymphoma	Phase2	Phase 2	1	—	—	2005-12
Leukemia	Phase2	Phase 2	23	—	—	1999-06
Malignant Breast Neoplasm	Phase2	Phase 2	3	—	—

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CDKN2A Loss1
Alvocidib	Cutaneous Melanoma

Clinical trials

Trials with this intervention (63)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 63 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02520011	Alvocidib Biomarker-driven Phase 2 AML Study	terminated	Phase 2	104	Sumitomo Pharma America, Inc.INDUSTRY	4	Nov 15, 2023	clinicaltrials
NCT03298984	Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).	completed	Phase 1

Molecule

Record

Kind: Small Molecule
Mechanism: Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor; Cyclin-dependent kinase 9 inhibitor; Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 7 inhibitor
Targets: 6 genes
Aliases: Alvocidib, Alvocidib Freebase, (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one, Flavopiridol, HL 275, HMR 1275, L 86 8275, L-868275, L86-8275, MDL 107,826A, MDL-107826A, NSC-649890

Data updated 15 minutes agoSource updated unknown

Identifiers

Codes (0)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

Data not yet available

No cross-reference code recorded yet beyond the record identifiers above.

Regulatory status is jurisdiction-specific and time-bound. Nothing on this page is a treatment recommendation.